Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 4Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Lymphoma, Non-Hodgkin 2Carcinoma, Basal Cell 2Breast Diseases 2Basal Cell Nevus Syndrome 2Upper Tract Urothelial Carcinomas 1Thrombocythemia, Essential 1Solid Tumors 1Serous Ovarian Cancer 1Recurrence 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Polycythemia Vera 1Ovarian Neoplasms 1Lymphedema 1Liver Neoplasms 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Hypogonadism 1Glioma 1Gastric Adenocarcinoma 1Fatigue Syndrome, Chronic 1Eunuchism 1Colonic Neoplasms 1Amyloidosis 1Adenoma 1

Interventions

infigratinib 1Drug Evaluation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Upper Tract Urothelial Carcinomas × Drug Evaluation × Clear all
NCT04197986 2024-03-13

PROOF302

QED Therapeutics, a BridgeBio company

Phase 3 Terminated
39 enrolled 31 charts
Genitourinary

Upper Tract Urothelial Carcinomas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡